Shots: The NMPA has approved Sulinno for the treatment of pJIA which is the fourth approved indication of the therapy in China. Earlier, Sulinno was approved for RA, PS, and […]readmore
Shots: The P-III HLX04-mCRC03 study involves assessing the efficacy, safety and immunogenicity of HLX04 vs reference bevacizumab (7.5 mg/kg, q3w or 5 mg/kg, q2w) + CT (Xelox or mFOLFOX6) as […]readmore
Shots: The designation allows Zai Lab to take advantage of an expedited approval procedure for Optune offering opportunities for pre-consultation with an input from the NMPA throughout the approval process […]readmore
Shots: Biomarin has received approval for its Vimizim, as a first approval by NMPA for patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome In May […]readmore
Copyright © 2020 Digiqole. All Right Reserved.